{"title":"超越低密度脂蛋白胆固醇水平:他汀类药物治疗对缺血性中风预后的影响。","authors":"Zi-Mo Chen, Jing-Lin Mo, Kai-Xuan Yang, Ying-Yu Jiang, Chun-Juan Wang, Xin Yang, Yong Jiang, Xia Meng, Jie Xu, Hao Li, Li-Ping Liu, Yi-Long Wang, Xing-Quan Zhao, Yong-Jun Wang, Hong-Qiu Gu, Zi-Xiao Li","doi":"10.1016/j.xinn.2024.100713","DOIUrl":null,"url":null,"abstract":"<p><p>Although essential for cardiovascular therapy, the pleiotropic effects of statins on ischemic stroke lack clinical evidence. This study examined the effects of statins beyond low-density lipoprotein cholesterol (LDL-C) levels on mortality and stroke severity. A total of 825,874 patients with ischemic stroke were included in this study, of whom 125,650 statin users were 1:1 matched with non-users based on their LDL-C levels (±0.05 mmol/L), forming the LDL-C-matched cohort. Associations between preceding statin treatment, in-hospital mortality, and stroke severity (National Institutes of Health Stroke Scale score ≥16) were estimated by multivariate and conditional logistic regression models in overall cohort and LDL-C-matched cohort, respectively. The overall statin effects reduced in-hospital mortality (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.65-0.79, <i>p</i> < 0.001) and moderate-to-severe stroke (OR: 0.93, 95% CI: 0.90-0.96, <i>p</i> < 0.001). After matching for LDL-C levels, the reduction in mortality persisted (OR: 0.63, 95% CI: 0.52-0.77, <i>p</i> < 0.001) but not for moderate-to-severe stroke (OR: 0.96, 95% CI: 0.90-1.02, <i>p</i> = 0.215). Stratified by LDL-C levels, the effects of statin beyond LDL-C in reducing mortality remained consistent across all LDL-C ranges but increased with LDL-C reduction for stroke severity and achieved statistical significance at LDL-C <2.60 mmol/L. Mediation analyses showed that LDL-C reduction explained 0.35% (95% CI: 0.23-0.93, <i>p</i> = 0.235) of the statin treatment-mortality relationship and 12.47% (95% CI: 6.78-18.16, <i>p</i> < 0.001) for moderate-to-severe stroke. When examining the overall statin efficacy, LDL-C <2.60 mmol/L was not necessary for mortality reduction but for reducing stroke severity. The efficacy of statins in ischemic stroke outcomes is primarily derived from their effects beyond the LDL-C levels, suggesting that their neuroprotective effects should be considered in addition to their lipid-lowering effects.</p>","PeriodicalId":36121,"journal":{"name":"The Innovation","volume":"5 6","pages":"100713"},"PeriodicalIF":33.2000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550173/pdf/","citationCount":"0","resultStr":"{\"title\":\"Beyond low-density lipoprotein cholesterol levels: Impact of prior statin treatment on ischemic stroke outcomes.\",\"authors\":\"Zi-Mo Chen, Jing-Lin Mo, Kai-Xuan Yang, Ying-Yu Jiang, Chun-Juan Wang, Xin Yang, Yong Jiang, Xia Meng, Jie Xu, Hao Li, Li-Ping Liu, Yi-Long Wang, Xing-Quan Zhao, Yong-Jun Wang, Hong-Qiu Gu, Zi-Xiao Li\",\"doi\":\"10.1016/j.xinn.2024.100713\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Although essential for cardiovascular therapy, the pleiotropic effects of statins on ischemic stroke lack clinical evidence. This study examined the effects of statins beyond low-density lipoprotein cholesterol (LDL-C) levels on mortality and stroke severity. A total of 825,874 patients with ischemic stroke were included in this study, of whom 125,650 statin users were 1:1 matched with non-users based on their LDL-C levels (±0.05 mmol/L), forming the LDL-C-matched cohort. Associations between preceding statin treatment, in-hospital mortality, and stroke severity (National Institutes of Health Stroke Scale score ≥16) were estimated by multivariate and conditional logistic regression models in overall cohort and LDL-C-matched cohort, respectively. The overall statin effects reduced in-hospital mortality (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.65-0.79, <i>p</i> < 0.001) and moderate-to-severe stroke (OR: 0.93, 95% CI: 0.90-0.96, <i>p</i> < 0.001). After matching for LDL-C levels, the reduction in mortality persisted (OR: 0.63, 95% CI: 0.52-0.77, <i>p</i> < 0.001) but not for moderate-to-severe stroke (OR: 0.96, 95% CI: 0.90-1.02, <i>p</i> = 0.215). Stratified by LDL-C levels, the effects of statin beyond LDL-C in reducing mortality remained consistent across all LDL-C ranges but increased with LDL-C reduction for stroke severity and achieved statistical significance at LDL-C <2.60 mmol/L. Mediation analyses showed that LDL-C reduction explained 0.35% (95% CI: 0.23-0.93, <i>p</i> = 0.235) of the statin treatment-mortality relationship and 12.47% (95% CI: 6.78-18.16, <i>p</i> < 0.001) for moderate-to-severe stroke. When examining the overall statin efficacy, LDL-C <2.60 mmol/L was not necessary for mortality reduction but for reducing stroke severity. The efficacy of statins in ischemic stroke outcomes is primarily derived from their effects beyond the LDL-C levels, suggesting that their neuroprotective effects should be considered in addition to their lipid-lowering effects.</p>\",\"PeriodicalId\":36121,\"journal\":{\"name\":\"The Innovation\",\"volume\":\"5 6\",\"pages\":\"100713\"},\"PeriodicalIF\":33.2000,\"publicationDate\":\"2024-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550173/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Innovation\",\"FirstCategoryId\":\"95\",\"ListUrlMain\":\"https://doi.org/10.1016/j.xinn.2024.100713\",\"RegionNum\":1,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/4 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Innovation","FirstCategoryId":"95","ListUrlMain":"https://doi.org/10.1016/j.xinn.2024.100713","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/4 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
虽然他汀类药物对心血管治疗至关重要,但其对缺血性中风的多效应却缺乏临床证据。本研究探讨了他汀类药物超出低密度脂蛋白胆固醇(LDL-C)水平对死亡率和中风严重程度的影响。本研究共纳入了 825,874 例缺血性中风患者,其中 125,650 例他汀类药物使用者与非使用者根据其低密度脂蛋白胆固醇水平(±0.05 mmol/L)进行了 1:1 匹配,形成了低密度脂蛋白胆固醇匹配队列。在总体队列和 LDL-C 匹配队列中,分别采用多变量和条件逻辑回归模型估计了之前他汀类药物治疗、院内死亡率和中风严重程度(美国国立卫生研究院中风量表评分≥16 分)之间的关系。他汀类药物的总体效果降低了院内死亡率(几率比 [OR]:0.72,95% 置信区间 [CI]:0.65-0.79,P P P = 0.215)。按 LDL-C 水平分层,他汀类药物超出 LDL-C 降低死亡率的效果在所有 LDL-C 范围内保持一致,但随着 LDL-C 降低,卒中严重程度增加,在 LDL-C p = 0.235 时,他汀类药物治疗与死亡率的关系达到统计学显著性,他汀类药物治疗与死亡率的关系达到 12.47% (95% CI: 6.78-18.16, p = 0.235)。
Beyond low-density lipoprotein cholesterol levels: Impact of prior statin treatment on ischemic stroke outcomes.
Although essential for cardiovascular therapy, the pleiotropic effects of statins on ischemic stroke lack clinical evidence. This study examined the effects of statins beyond low-density lipoprotein cholesterol (LDL-C) levels on mortality and stroke severity. A total of 825,874 patients with ischemic stroke were included in this study, of whom 125,650 statin users were 1:1 matched with non-users based on their LDL-C levels (±0.05 mmol/L), forming the LDL-C-matched cohort. Associations between preceding statin treatment, in-hospital mortality, and stroke severity (National Institutes of Health Stroke Scale score ≥16) were estimated by multivariate and conditional logistic regression models in overall cohort and LDL-C-matched cohort, respectively. The overall statin effects reduced in-hospital mortality (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.65-0.79, p < 0.001) and moderate-to-severe stroke (OR: 0.93, 95% CI: 0.90-0.96, p < 0.001). After matching for LDL-C levels, the reduction in mortality persisted (OR: 0.63, 95% CI: 0.52-0.77, p < 0.001) but not for moderate-to-severe stroke (OR: 0.96, 95% CI: 0.90-1.02, p = 0.215). Stratified by LDL-C levels, the effects of statin beyond LDL-C in reducing mortality remained consistent across all LDL-C ranges but increased with LDL-C reduction for stroke severity and achieved statistical significance at LDL-C <2.60 mmol/L. Mediation analyses showed that LDL-C reduction explained 0.35% (95% CI: 0.23-0.93, p = 0.235) of the statin treatment-mortality relationship and 12.47% (95% CI: 6.78-18.16, p < 0.001) for moderate-to-severe stroke. When examining the overall statin efficacy, LDL-C <2.60 mmol/L was not necessary for mortality reduction but for reducing stroke severity. The efficacy of statins in ischemic stroke outcomes is primarily derived from their effects beyond the LDL-C levels, suggesting that their neuroprotective effects should be considered in addition to their lipid-lowering effects.
期刊介绍:
The Innovation is an interdisciplinary journal that aims to promote scientific application. It publishes cutting-edge research and high-quality reviews in various scientific disciplines, including physics, chemistry, materials, nanotechnology, biology, translational medicine, geoscience, and engineering. The journal adheres to the peer review and publishing standards of Cell Press journals.
The Innovation is committed to serving scientists and the public. It aims to publish significant advances promptly and provides a transparent exchange platform. The journal also strives to efficiently promote the translation from scientific discovery to technological achievements and rapidly disseminate scientific findings worldwide.
Indexed in the following databases, The Innovation has visibility in Scopus, Directory of Open Access Journals (DOAJ), Web of Science, Emerging Sources Citation Index (ESCI), PubMed Central, Compendex (previously Ei index), INSPEC, and CABI A&I.